143 related articles for article (PubMed ID: 34216422)
1. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C.
Yamashita Y; Joshita S; Sugiura A; Yamazaki T; Kobayashi H; Wakabayashi SI; Yamada Y; Shibata S; Kunimoto H; Iwadare T; Matsumura M; Miyabayashi C; Okumura T; Ozawa S; Nozawa Y; Kobayashi N; Komatsu M; Fujimori N; Saito H; Umemura T
Hepatol Res; 2021 Sep; 51(9):933-942. PubMed ID: 34216422
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria.
Ohama H; Hiraoka A; Tada F; Kato K; Fukunishi Y; Yanagihara E; Kato M; Saneto H; Izumoto H; Ueki H; Yoshino T; Kitahata S; Kawamura T; Kuroda T; Suga Y; Miyata H; Hirooka M; Abe M; Matsuura B; Ninomiya T; Hiasa Y
Oncology; 2023; 101(9):575-583. PubMed ID: 37459848
[TBL] [Abstract][Full Text] [Related]
3. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
5. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus.
Yasui Y; Kurosaki M; Komiyama Y; Takada H; Tamaki N; Watakabe K; Okada M; Wang W; Shimizu T; Kubota Y; Higuchi M; Takaura K; Tsuchiya K; Nakanishi H; Takahashi Y; Itakura J; Enomoto N; Izumi N
Hepatol Res; 2018 Dec; 48(13):1131-1139. PubMed ID: 30030872
[TBL] [Abstract][Full Text] [Related]
6. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
Dang H; Yeo YH; Yasuda S; Huang CF; Iio E; Landis C; Jun DW; Enomoto M; Ogawa E; Tsai PC; Le A; Liu M; Maeda M; Nguyen B; Ramrakhiani N; Henry L; Cheung R; Tamori A; Kumada T; Tanaka Y; Yu ML; Toyoda H; Nguyen MH
Hepatology; 2020 Jun; 71(6):1910-1922. PubMed ID: 31610027
[TBL] [Abstract][Full Text] [Related]
7. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
8. Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection.
Innes H; Jepsen P; McDonald S; Dillon J; Hamill V; Yeung A; Benselin J; Went A; Fraser A; Bathgate A; Ansari MA; Barclay ST; Goldberg D; Hayes PC; Johnson P; Barnes E; Irving W; Hutchinson S; Guha IN
JHEP Rep; 2021 Dec; 3(6):100384. PubMed ID: 34805817
[TBL] [Abstract][Full Text] [Related]
9. External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy.
Gui H; Huang Y; Zhao G; Chen L; Cai W; Wang H; Guo Q; Xie Q
Front Med (Lausanne); 2021; 8():677920. PubMed ID: 34422855
[No Abstract] [Full Text] [Related]
10. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
Fan R; Chen L; Zhao S; Yang H; Li Z; Qian Y; Ma H; Liu X; Wang C; Liang X; Bai J; Xie J; Fan X; Xie Q; Hao X; Wang C; Yang S; Gao Y; Bai H; Dou X; Liu J; Wu L; Jiang G; Xia Q; Zheng D; Rao H; Xia J; Shang J; Gao P; Xie D; Yu Y; Yang Y; Gao H; Liu Y; Sun A; Jiang Y; Yu Y; Niu J; Sun J; Wang H; Hou J
J Hepatol; 2023 Oct; 79(4):933-944. PubMed ID: 37302583
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
[TBL] [Abstract][Full Text] [Related]
15. Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study.
Xin Y; Zhang X; Yang Y; Chen Y; Wang Y; Zhou X; Li X
J Gastrointest Oncol; 2021 Dec; 12(6):2930-2942. PubMed ID: 35070419
[TBL] [Abstract][Full Text] [Related]
16. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study.
Tani J; Morishita A; Sakamoto T; Takuma K; Nakahara M; Fujita K; Oura K; Tadokoro T; Mimura S; Nomura T; Yoneyama H; Kobara H; Himoto T; Tsutsui A; Senoh T; Nagano T; Ogawa C; Moriya A; Deguchi A; Takaguchi K; Masaki T
Oncol Lett; 2020 Mar; 19(3):2205-2212. PubMed ID: 32194718
[TBL] [Abstract][Full Text] [Related]
17. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals.
Syed T; Fazili J; Ali IA; Zhao D; Hughes D; Mahmood S
Cureus; 2018 Jun; 10(6):e2843. PubMed ID: 30280052
[TBL] [Abstract][Full Text] [Related]
19. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
20. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
Chun HS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee CH; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Lee JH; Kim SU
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):378-385. PubMed ID: 32011388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
